SymbioCellTech is a groundbreaking brand that specializes in stem cell-based biologic therapy for Type-1 diabetes. They have developed and patented a unique technology called Neo-Islets, which combines allogeneic Pancreatic Beta Cells and Mesenchymal Stem Cells (MSC) into hybrid clusters. When administered into the abdominal cavity, these Neo-Islets not only produce physiologically regulated insulin but also provide immune isolation from destructive immunosurveillance.

Unlike traditional treatments, SymbioCellTech's therapy offers a durable solution that aims to restore pancreatic function and achieve euglycemia in diabetic patients. Their preclinical studies have shown promising results, with Neo-Islets functionally curing Type-1 diabetes in pet dogs and reducing the need for insulin by up to 50%. Moreover, the therapy can be administered as a simple outpatient procedure, offering a convenient and long-lasting treatment option.

SymbioCellTech's technology overcomes major technical obstacles faced by cell-based diabetes therapies, including immune attack, scarcity of donors, limited vascularization, and sub-optimal insulin delivery. With plans to begin human clinical trials in 2023, SymbioCellTech is at the forefront of revolutionizing diabetes treatment and providing hope for a better future